Maarten van der Doelen

Chapter 2

ACKNOWLEDGEMENTS The authors acknowledge the nuclear medicine staff and nurses at the University Hospital Heidelberg and all the patients and their partners who agreed to participate in the study.We also thank the department of Pathology at the RadboudUniversityMedical Center, in particular Muradiye Demirel-Andishmand, for the immunohistochemical stainings. We thank Hanneke Geurts, department of Medical Psychology, Radboud University Medical Center, for her help with analyzing the quality of life data. We thank ABX (Radeberg, Germany) for providing the software (ROVER) for the semi-quantitative PET analysis. We thank the patient advocates of the Dutch prostate cancer foundation for their interest in this study. This publication and the underlying study have been made possible partly on the basis of the data that Hartwig Medical Foundation and the Center of Personalised Cancer Treatment (CPCT) have made available to the study. We would like to thank the CPCT team of bioinformatics, in particular Korneel Duyvesteyn, for his help with interpreting the data. We thank Foundation Medicine for sequencing additional tissue samples.

42